As Cancers (ISSN: 2072-6694) is an open access journal, you have free and unlimited access to the full text of all articles. We welcome you to read our feature papers in the Section “Cancer Pathophysiology” from the first half of 2024, which are listed below:

1. “Application of Nanoparticles for Magnetic Hyperthermia for Cancer Treatment—The Current State of Knowledge”
by Marzena Szwed and Agnieszka Marczak
Cancers 2024, 16(6), 1156; https://doi.org/10.3390/cancers16061156
Available online: https://www.mdpi.com/2072-6694/16/6/1156

2. “Machine Learning-Based Assessment of Survival and Risk Factors in Non-Alcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma for Optimized Patient Management”
by Miguel Suárez, Sergio Gil-Rojas, Pablo Martínez-Blanco, Ana M. Torres, Antonio Ramón, Pilar Blasco-Segura, Miguel Torralba and Jorge Mateo
Cancers 2024, 16(6), 1114; https://doi.org/10.3390/cancers16061114
Available online: https://www.mdpi.com/2072-6694/16/6/1114

3. “MALAT-1 Is a Key Regulator of Epithelial–Mesenchymal Transition in Cancer: A Potential Therapeutic Target for Metastasis”
by Mohamed Ali Hussein, Kamyab Valinezhad, Eman Adel and Gnanasekar Munirathinam
Cancers 2024, 16(1), 234; https://doi.org/10.3390/cancers16010234
Available online: https://www.mdpi.com/2072-6694/16/1/234

4. “Metabolic Dysfunction-Associated Steatohepatitis and Progression to Hepatocellular Carcinoma: A Literature Review”
by Haider Ghazanfar, Nismat Javed, Abeer Qasim, George Sarin Zacharia, Ali Ghazanfar, Abhilasha Jyala, Elona Shehi and Harish Patel
Cancers 2024, 16(6), 1214; https://doi.org/10.3390/cancers16061214
Available online: https://www.mdpi.com/2072-6694/16/6/1214

5. “PRAME Is an Effective Tool for the Diagnosis of Nevus-Associated Cutaneous Melanoma”
by Andrea Ronchi, Gerardo Cazzato, Giuseppe Ingravallo, Giuseppe D’Abbronzo, Giuseppe Argenziano, Elvira Moscarella, Gabriella Brancaccio and Renato Franco
Cancers 2024, 16(2), 278; https://doi.org/10.3390/cancers16020278
Available online: https://www.mdpi.com/2072-6694/16/2/278

6. “17q Gain in Neuroblastoma: A Review of Clinical and Biological Implications”
by Vid Mlakar, Isabelle Dupanloup, Fanny Gonzales, Danai Papangelopoulou, Marc Ansari and Fabienne Gumy-Pause
Cancers 2024, 16(2), 338; https://doi.org/10.3390/cancers16020338
Available online: https://www.mdpi.com/2072-6694/16/2/338

7. “Biomarkers in the Diagnosis of Endometrial Precancers. Molecular Characteristics, Candidate Immunohistochemical Markers, and Promising Results of Three-Marker Panel: Current Status and Future Directions”
by Shuang Niu, Kyle Molberg, Diego H. Castrillon, Elena Lucas and Hao Chen
Cancers 2024, 16(6), 1159; https://doi.org/10.3390/cancers16061159
Available online: https://www.mdpi.com/2072-6694/16/6/1159

8. “Synergy between BRD9- and IKZF3-Targeting as a Therapeutic Strategy for Multiple Myeloma”
by Basudev Chowdhury, Swati Garg, Wei Ni, Martin Sattler, Dana Sanchez, Chengcheng Meng, Taisei Akatsu, Richard Stone, William Forrester, Edmund Harrington et al.
Cancers 2024, 16(7), 1319; https://doi.org/10.3390/cancers16071319
Available online: https://www.mdpi.com/2072-6694/16/7/1319

9. “From Diabetes to Oncology: Glucagon-like Peptide-1 (GLP-1) Receptor Agonist’s Dual Role in Prostate Cancer”
by Abdulrahman Alhajahjeh, Raad Al-Faouri, Hisham F. Bahmad, Taima’ Bader, Ryan W. Dobbs, Ahmed A. Abdulelah, Wassim Abou-Kheir, Elai Davicioni, David I. Lee and Mohammed Shahait
Cancers 2024, 16(8), 1538; https://doi.org/10.3390/cancers16081538
Available online: https://www.mdpi.com/2072-6694/16/8/1538

10. “Significant and Various Effects of ML329-Induced MITF Suppression in the Melanoma Cell Line”
by Nami Nishikiori, Megumi Watanabe, Tatsuya Sato, Masato Furuhashi, Masae Okura, Tokimasa Hida, Hisashi Uhara and Hiroshi Ohguro
Cancers 2024, 16(2), 263; https://doi.org/10.3390/cancers16020263
Available online: https://www.mdpi.com/2072-6694/16/2/263

You can view and submit relevant papers to Cancers via https://www.mdpi.com/journal/cancers.

Cancers Editorial Office